Leonhardt Ventures
  • Home
  • About
    • About us
    • 2021 Top Achievements
    • Leonhardt Ventures Portfolio Clinical Trials Listing
    • Founder Bio
    • Development Pipeline
    • Regenerative Medtech
    • Media
      • Company Logos
    • LV Team
      • Board of Directors
      • Team
      • Accelerator Core Team
      • Portfolio Startups Boards
      • Scientific Advisory Board
  • Our Startups
  • News
  • Investors
    • Invest in us
    • Agreements & Forms
      • Agreement Forms
      • Master Patent IP License and Development Agreement
      • Accelerator Membership Agreement
      • Term Sheet
      • 409a Valuation Accelerator
      • Simple Agreement for Future Equity
        • Simple Agreement for Future Equity – Word
        • Simple Agreement for Future Equity – PDF
    • Leonhardts Launchpads
      • Leonhardt’s Launchpads Valuations
      • Accelerator Business Model
      • Cap Tables and Valuations
    • Important
      • 2023 Budget
      • 2022 Budget
      • 2022 Compared YTD Budget
      • Legal Terms Summary
      • Executive Chairman’s 2022 Update
      • Executive Chairman’s Best guess estimate June 2022 on portfolio assets closest to exit
      • Board Governance
      • 2023 Goals
      • Current Clinical Trials
      • Executive Summary
    • Clinical Studies
      • Clinical Study Enrollment 10/1/19
    • Annual Reports
      • 2020-2023
        • 2023 Annual Report
        • Mid-Year 2022 Semi-Annual Report
        • 2022 Annual Report Executive Summary
        • 2021 Annual Report
        • 2020 Annual Report
      • 2016 – 2019
        • 2019 Annual Report
        • 2018 Annual Report
        • 2017 Annual Report
        • 2016 Annual Report
      • 2012-2015
        • 2015/16 Annual report
        • 1Q 2015 Newsletter
        • 2013/14 Annual Newsletter
        • 2012 Fall Newsletter
    • Investor FAQ
    • Leonhardt Ventures LLC Patent Licenses 2022
  • Contact
Select Page

Leonhardt Ventures Announces Launch of Research Program Using Patent Pending Klotho Expressing Mesenchymal Stem Cells for Multiple Applications in Combination with Bioelectric Protein Expressions

by hleonhardt | Feb 2, 2022 | News

Mission Viejo, California, United States, Jan. 26, 2022 (GLOBE NEWSWIRE) — Leonhardt Ventures LLC, a Mission Viejo, California based company via it’s innovation and startup launch accelerator Leonhardt’s Launchpads, announced today that it has begun...

Leonhardt Ventures LLC Issued Pioneering Patent for Bioelectric Inflammation Treatment Device and Method

by hleonhardt | Jan 19, 2022 | News

Irvine, California, United States – 09/07/2021 — Patent protects methods and devices for customized real time treatment of chronic inflammation related disorders with bioelectric stimulation based protein expressions and control  Irvine, California...

Leonhardt’s Launchpads Announces Issuance of New U.S. Patent for Bioelectric Plus Biologics Platform for Organ Regeneration and Healing

by hleonhardt | Jan 19, 2022 | News

Latest Patent Further Strengthens Intellectual Property Portfolio Covering Novel Platform for Precisely Controlling Regenerative Protein Expressions Including Stem Cell Homing and Differentiation Control Technology Has Key Potential Applications in Regeneration of...

Leonhardt’s Launchpads Accelerator To Showcase Eight Innovation Assets and Startups At 2022 Demo Day

by hleonhardt | Jan 19, 2022 | News

Showcased technologies include a novel circulatory assist pump for heart failure and bioelectric and biologic treatments for erectile dysfunction, skin and hair regeneration, and rapid straightening and stabilization of teeth during orthodontic treatment.  NEWS...

Leonhardt Ventures Announces Issuance of Pioneering U.S. Patent for Multi-Modality Customized Bioelectric Treatment of Cancer

by hleonhardt | Jan 19, 2022 | News

Published: Dec 22, 2021 Mission Viejo, California, United States, Dec. 22, 2021 (GLOBE NEWSWIRE) — Leonhardt Ventures LLC, a pioneer in developing bioelectric and biologic innovations for organ regeneration and healing, today announced that the U.S. Patent and...
« Older Entries
Next Entries »

Recent Posts

  • Executive Chairman’s Best guess estimate June 2023 on portfolio assets closest to exit
  • 2023 Annual Shareholder Meeting.
  • Episode 138: Howard Leonhardt – The Future of Longevity & Wellness is Here!
  • 1Q 2023 Update Letter to Shareholders for accelerator and portfolio
  • BodStim Suits Up To Revolutionize Fitness And Shows Significant Promise For Enhancing Longevity
  • Facebook
  • X
© Copyright Leonhardt Ventures | Website by FizzPOP Media